Biofrontera AG

B8FK

Company Profile

  • Business description

    Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

  • Contact

    Hemmelrather Weg 201
    LeverkusenNW51377
    DEU

    T: +49 214876320

    E: [email protected]

    https://www.biofrontera.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    76

Stocks News & Analysis

stocks

Earnings losers: TWE, GMG, SUN and more fall on weaker profits

Where companies fell short of market expectations in the third week of earnings.
stocks

Overvalued ASX listed gold miner reports lower profit

Shares remain materially overvalued.
stocks

ASX healthcare leader still undervalued after rally

Our view following announcement of potential spinoff.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,251.5083.10-0.89%
CAC 408,515.49116.711.39%
DAX 4025,260.69217.120.87%
Dow JONES (US)49,625.97230.810.47%
FTSE 10010,686.8959.850.56%
HKSE27,111.08697.732.64%
NASDAQ22,886.07203.340.90%
Nikkei 22556,825.70642.13-1.12%
NZX 50 Index13,420.43111.910.84%
S&P 5006,909.5147.620.69%
S&P/ASX 2009,026.0084.10-0.92%
SSE Composite Index4,082.0751.95-1.26%

Market Movers